Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
申请人:——
公开号:US20030152611A1
公开(公告)日:2003-08-14
The invention concerns a pharmaceutical composition for transdermal administration comprising: a polymeric release matrix capable of forming a soft film after drying, selected among cellulose polymers or copolymers, said matrix being present at a concentration not exceeding 6% of the composition weight; an active principle selected among the group of non-steroid anti-inflammatory agents comprising at least a metal carboxylic or carboxitate group; a transcutaneous absorption promoter of the active principle; water; and at least a physiologically acceptable non-aqueous solvent capable of dissolving the release matrix, the active principle and transcutaneous absorption promoter and to be rapidly eliminated by evaporation in contact with the skin.
Pharmaceutical composition for transdermal administration
申请人:Sanofi
公开号:US06010716A1
公开(公告)日:2000-01-04
The invention concerns a pharmaceutical composition for transdermal administration, characterized in that it comprises: a) optionally, a polymeric release matrix capable of forming a flexible film after drying, chosen from cellulose polymers or copolymers or vinylpyrrolidone/vinyl acetate copolymers b) an active principle c) a promoter of transcutaneous absorption of the active principle d) a physiologically acceptable non-aqueous solvent capable of dissolving the release matrix, the active principle and the transcutaneous absorption promoter and also capable of being rapidly removed by evaporation on contact with the skin.
Prostaglandin and hydroxylated fatty acid ester formulations
申请人:AMERICAN CYANAMID COMPANY
公开号:EP0112451A2
公开(公告)日:1984-07-04
Degradation of E-type prostaglandin compounds is retarded by dissolving or suspending such compounds in formulations containing hydroxylated derivatives of fatty acids having the formula:
wherein R1 is C2-C24 alkyl, R2 is C2-C24 alkyl and n is an integer from 1-6, denoting from to 6 hydroxyl groups which may be substituted in R, or R2.
将 E 型前列腺素化合物溶解或悬浮在含有脂肪酸羟基化衍生物的制剂中,可以延缓 E 型前列腺素化合物的降解,脂肪酸羟基化衍生物的分子式为: 其中 R1 为 C2-C24 烷基,R2 为 C2-C24 烷基,n 为 1-6 之间的整数,表示 R 或 R2 中可被取代的羟基数为 6。
Cleansing agents
申请人:SHISEIDO COMPANY LIMITED
公开号:EP1129686A1
公开(公告)日:2001-09-05
Providing cleansing agents which are highly effective for removing makeup with excellent lathering and give refreshing after-shampoo feelings. The cleansing agents comprises surfactants and polyoxyalkylene carboxylic acid ester represented by the following general formula (1);
wherein R1 and R2 are hydrogen or alkyl or branched alkyl groups of 1 to 4 carbon atoms; m, n, X and Y are integers from 0 to 5 but are not concurrently 0; and R3 is a branched or straight alkylene group of 0 to 10 carbon atoms.
Compositions for controlling phytoplankton contamination
申请人:BLUEGREEN WATER TECHNOLOGIES LTD.
公开号:US11154053B2
公开(公告)日:2021-10-26
A composition for mitigating, inhibiting, ameliorating and/or eliminating phytoplankton growth in a waterbody, the composition comprising an active ingredient at concentration of 80.0-99.5% (w/w) of the composition and a coating material at concentration of 0.5-20% (w/w) of the composition; wherein the critical surface tension of the composition is between 15-60 dyn/cm and wherein the relative density of the composition, prior to being submerged in water, is above 1 g/cm3.